Structural, functional and patient-reported 24-month outcomes of voretigene neparvovec in Portuguese patients with RPE65-associated disease
{{output}}
Background/objectives: Voretigene neparvovec (VN) is a one-time gene therapy for biallelic RPE65-associated retinal degeneration (RPE65-RD). This study evaluated the real-world safety, effectiveness, and patient-reported outcomes... ...
